共 45 条
[41]
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
[J].
CANCER RESEARCH AND TREATMENT,
2016, 48 (04)
:1177-1186
[42]
REVEL: A Randomized, Double-Blind, Phase III Study of Docetaxel (DOC) and Ramucirumab (RAM; IMC-1121B) Versus DOC and Placebo (PL) in the Second-Line Treatment of Stage IV Non-Small Cell Lung Cancer (NSCLC) Following Disease Progression After One Prior Platinum-Based Therapy
[J].
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY,
2014, 12 (10)
:10-12
[43]
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2014, 32 (15)
[44]
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2014, 32 (18)
[45]
Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2024, 42 (3_SUPPL)
:372-372